Cargando…

Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma

AIM: To assess the safety and efficacy of transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment. METHODS: Drug eluting bead TACE (DEB-TACE) using a new generation of microspheres (em...

Descripción completa

Detalles Bibliográficos
Autores principales: Greco, Giorgio, Cascella, Tommaso, Facciorusso, Antonio, Nani, Roberto, Lanocita, Rodolfo, Morosi, Carlo, Vaiani, Marta, Calareso, Giuseppina, Greco, Francesca G, Ragnanese, Antonio, Bongini, Marco A, Marchianò, Alfonso V, Mazzaferro, Vincenzo, Spreafico, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441456/
https://www.ncbi.nlm.nih.gov/pubmed/28634515
http://dx.doi.org/10.4329/wjr.v9.i5.245
_version_ 1783238266741325824
author Greco, Giorgio
Cascella, Tommaso
Facciorusso, Antonio
Nani, Roberto
Lanocita, Rodolfo
Morosi, Carlo
Vaiani, Marta
Calareso, Giuseppina
Greco, Francesca G
Ragnanese, Antonio
Bongini, Marco A
Marchianò, Alfonso V
Mazzaferro, Vincenzo
Spreafico, Carlo
author_facet Greco, Giorgio
Cascella, Tommaso
Facciorusso, Antonio
Nani, Roberto
Lanocita, Rodolfo
Morosi, Carlo
Vaiani, Marta
Calareso, Giuseppina
Greco, Francesca G
Ragnanese, Antonio
Bongini, Marco A
Marchianò, Alfonso V
Mazzaferro, Vincenzo
Spreafico, Carlo
author_sort Greco, Giorgio
collection PubMed
description AIM: To assess the safety and efficacy of transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment. METHODS: Drug eluting bead TACE (DEB-TACE) using a new generation of microspheres (embozene tandem, 40 μm) preloaded with 100 mg of doxorubicin was performed on 48 early or intermediate HCC patients with compensated cirrhosis. Response to therapy was assessed with Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) guidelines applied to computed tomography or magnetic resonance imaging. Eleven out of the 48 treated patients treated progressed on to receive liver orthotopic transplantation (OLT). This allowed for histological analysis on the treated explanted nodules. RESULTS: DEB-TACE with 40 μm showed a good safety profile without major complications or 30-d mortality. The objective response rate of treated tumors was 72.6% and 26.7% according to mRECIST and RECIST respectively. Histological examination in 11 patients assigned to OLT showed a necrosis degree > 90% in 78.6% of cases. The overall time to progression was 13 mo (11-21). CONCLUSION: DEB-TACE with 40 μm particles is an effective treatment for the treatment of HCC in early-intermediate patients (Barcelona Clinic Liver Cancer stage A/B) with a good safety profile and good results in term of objective response rate and necrosis.
format Online
Article
Text
id pubmed-5441456
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-54414562017-06-21 Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma Greco, Giorgio Cascella, Tommaso Facciorusso, Antonio Nani, Roberto Lanocita, Rodolfo Morosi, Carlo Vaiani, Marta Calareso, Giuseppina Greco, Francesca G Ragnanese, Antonio Bongini, Marco A Marchianò, Alfonso V Mazzaferro, Vincenzo Spreafico, Carlo World J Radiol Retrospective Study AIM: To assess the safety and efficacy of transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment. METHODS: Drug eluting bead TACE (DEB-TACE) using a new generation of microspheres (embozene tandem, 40 μm) preloaded with 100 mg of doxorubicin was performed on 48 early or intermediate HCC patients with compensated cirrhosis. Response to therapy was assessed with Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) guidelines applied to computed tomography or magnetic resonance imaging. Eleven out of the 48 treated patients treated progressed on to receive liver orthotopic transplantation (OLT). This allowed for histological analysis on the treated explanted nodules. RESULTS: DEB-TACE with 40 μm showed a good safety profile without major complications or 30-d mortality. The objective response rate of treated tumors was 72.6% and 26.7% according to mRECIST and RECIST respectively. Histological examination in 11 patients assigned to OLT showed a necrosis degree > 90% in 78.6% of cases. The overall time to progression was 13 mo (11-21). CONCLUSION: DEB-TACE with 40 μm particles is an effective treatment for the treatment of HCC in early-intermediate patients (Barcelona Clinic Liver Cancer stage A/B) with a good safety profile and good results in term of objective response rate and necrosis. Baishideng Publishing Group Inc 2017-05-28 2017-05-28 /pmc/articles/PMC5441456/ /pubmed/28634515 http://dx.doi.org/10.4329/wjr.v9.i5.245 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Greco, Giorgio
Cascella, Tommaso
Facciorusso, Antonio
Nani, Roberto
Lanocita, Rodolfo
Morosi, Carlo
Vaiani, Marta
Calareso, Giuseppina
Greco, Francesca G
Ragnanese, Antonio
Bongini, Marco A
Marchianò, Alfonso V
Mazzaferro, Vincenzo
Spreafico, Carlo
Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma
title Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma
title_full Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma
title_fullStr Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma
title_full_unstemmed Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma
title_short Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma
title_sort transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441456/
https://www.ncbi.nlm.nih.gov/pubmed/28634515
http://dx.doi.org/10.4329/wjr.v9.i5.245
work_keys_str_mv AT grecogiorgio transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma
AT cascellatommaso transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma
AT facciorussoantonio transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma
AT naniroberto transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma
AT lanocitarodolfo transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma
AT morosicarlo transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma
AT vaianimarta transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma
AT calaresogiuseppina transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma
AT grecofrancescag transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma
AT ragnaneseantonio transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma
AT bonginimarcoa transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma
AT marchianoalfonsov transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma
AT mazzaferrovincenzo transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma
AT spreaficocarlo transarterialchemoembolizationusing40μmdrugelutingbeadsforhepatocellularcarcinoma